bosentan anhydrous has been researched along with glyburide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chagneau, C; De Gottardi, A; Fléjou, JF; Fouassier, L; Housset, C; Lahaye, P; Lebrec, D; Moreau, R; Reichen, J; Rona, JP; Tazi, KA | 1 |
| Fattinger, K; Funk, C; Meier, PJ; Pantze, M; Reichen, J; Stieger, B; Weber, C | 1 |
| Bodin, F; Clozel, M; Dingemanse, J; Treiber, A; van Giersbergen, PL | 1 |
| Dingemanse, J; Gnerre, C; Meyer, UA; Treiber, A; van Giersbergen, PL | 1 |
| Kim, SH; Lee, GJ; Li, W; Park, BM; Yu, L | 1 |
1 review(s) available for bosentan anhydrous and glyburide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for bosentan anhydrous and glyburide
| Article | Year |
|---|---|
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
Topics: Adolescent; Adult; Analysis of Variance; Area Under Curve; Binding, Competitive; Bosentan; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Endothelin Receptor Antagonists; Female; Glyburide; Humans; Hypoglycemic Agents; Isoenzymes; Male; Microsomes, Liver; Receptors, Endothelin; Sulfonamides | 2002 |
12 other study(ies) available for bosentan anhydrous and glyburide
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Endothelium-dependent blunted membrane potential responses to ATP-sensitive K+ channel modulators in aortae from rats with cirrhosis.
Topics: Adenosine Triphosphate; Animals; Aorta; Bosentan; Cromakalim; Diazoxide; Endothelin-1; Endothelium, Vascular; Glyburide; Liver Cirrhosis, Experimental; Male; Membrane Potentials; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Sulfonamides; Tolbutamide | 1999 |
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Bile Canaliculi; Bosentan; Cholestasis, Intrahepatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Endothelin Receptor Antagonists; Glyburide; Humans; Hypertension; Liver; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sulfonamides; Taurocholic Acid | 2001 |
Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.
Topics: Animals; Bosentan; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Glyburide; Hepatocytes; Humans; Hypoglycemic Agents; Mice; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Sulfonamides | 2002 |
Hypoxia augments NaHS-induced ANP secretion via KATP channel, HIF-1α and PPAR-γ pathway.
Topics: 2-Methoxyestradiol; Anilides; Animals; Atrial Natriuretic Factor; Bosentan; Gene Expression Regulation; Glyburide; Heart Atria; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; KATP Channels; Male; Monocrotaline; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Organ Culture Techniques; Oxygen; Pinacidil; Potassium Channel Blockers; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfides | 2019 |